Newron Pharmaceuticals Starts Preclinicals on Compound with Psychiatric Treatment Potential

December 3, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ZURICH (Thomson Financial) - Newron Pharmaceuticals Spa said it has started preclinical development of a compound called NW-3509, which could potentially be used to treat psychiatric and neurological diseases, such as acute mania.

Twitter
LinkedIn
Facebook
Email
Print

Preclinical Europe